QualityStocksNewsBreaks – CytoDyn Inc. (CYDY) Expanding Focus Beyond HIV through Planned Acquisition
CytoDyn (OTCQB: CYDY), a biotechnology company developing a novel humanized CCR5 monoclonal antibody for multiple therapeutic indications, is now gearing up to further target life-threatening diseases through a potential acquisition. A recent article discussing the company reads, “With its planned acquisition of ProstaGene, LLC, CytoDyn Inc. (OTCQB: CYDY) is expanding its focus beyond HIV and graft-versus-host disease to open up a new front in the fight against cancer. ProstaGene is developing metastasis control technology that targets the chemokine receptor type 5 (CCR5), a protein on the surface of white blood cells. Metastasis is the spread of cancer beyond the original…